Journals / GORM:Gynecology Obstetrics & Reproductive Medicine / 2005 / Cilt: 11 - Sayı: 2

Spectroscopy analysis of uterine leiomyomas before and after treatment with GnRH-a

Pages
141–144
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The presence of lipid signals and absence of other signals suggest a diffuse metabolic defect in association with GnRHa treatment, possibly consistent with decrease in myoflaments, and increase in apopitosis and necrosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:MR spectroscopy uses the same hardware as magnetic resonance imaging but provides information at the biochemical level.
📊
Key Findings & Data:Subcutaneous goserelin acetate injection was performed at least two times every 4 weeks before surgery.
💡
Conclusion & Impact:The presence of lipid signals and absence of other signals suggest a diffuse metabolic defect in association with GnRHa treatment, possibly consistent with decrease in myoflaments, and increase in apopitosis and necrosis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Goserelin · Magnetik rezonans spektroskopi · Gonadotropin-serbestleştirici hormon

Abstract

MR spectroscopy uses the same hardware as magnetic resonance imaging but provides information at the biochemical level. It has been used to measure proton-containing compounds, such as amino acids, fatty acids, organic acids, sugars and other metabolic active compounds in tissue specimens. Before and after GnRH-a treatment we measured lipid, lactate, creatine and choline concentrations in two patients with uterine leiomyomas using single-voxel proton MR spectroscopy. Subcutaneous goserelin acetate injection was performed at least two times every 4 weeks before surgery. Spectroscopy was performed 3 weeks later last goserelin acetate injection. The MR spectroscopy results of leiomyomas before and after GnRH-a treatment were compared. Before GnRH-a treatment, spectral analysis of each patients showed only choline signals. After GnRH-a treatment, spectrum of both patients showed lipid peaks but the other signals were not observed. The presence of lipid signals and absence of other signals suggest a diffuse metabolic defect in association with GnRHa treatment, possibly consistent with decrease in myoflaments, and increase in apopitosis and necrosis.

🔖

Cite This Article

HASÇALIK, Ş., ÇELİK, Ö., SARAÇ, K., ALKAN, A., MIZRAK, B. (2005). Spectroscopy analysis of uterine leiomyomas before and after treatment with GnRH-a. GORM:Gynecology Obstetrics & Reproductive Medicine, Cilt: 11 - Sayı: 2, 141–144. https://ajindex.com/articles/227140

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Burtscher IM, Holtas S. Proton MR spectroscopy in clinical routine. J Magn Reson Imaging 2001
  2. Gotsis ED, Fountas K, Kapsalaki E, Toulas P, Peristeris G, Papadakis N. In vivo proton MR spectroscopy: the diagnostic possibilities of lipid resonances in brain tumors. Anticancer Res 1996
  3. Okada T, Harada M, Matsuzaki K, Nishitani H, Aono T. Evaluation of female intrapelvic tumors by clinical proton MR spectroscopy. J Magn Reson Imaging 2001
  4. Adamson GD. Treatment of uterine fibroids: current findings with gonadotropin-releasing hormone agonists. Am J Obstet Gynecol 1992
  5. Friedman AJ, Lobel SM, Rein MS, Barbieri RL. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis. Am J Obstet Gynecol. 1990
  6. Çelik O, Saraç K, Hascalik S, Alkan A, Mizrak B, Yologlu S. Magnetic Resonance Spectroscopy Features of Uterine Leiomyomas. Gynecol Obstet Invest. 2004
  7. 29 [Epub ahead of print] 7.Hricak H, Tscholakoff D, Heinrichs L, et al. Uterine leiomyomas: correlation of MR, histopathologic findings, and symptoms. Radiology 1986
  8. Persaud V, Arjoon PD. Uterine leiomyoma. Incidence of degenerative change and a correlation of associated symptoms. Obstet Gynecol 1970
  9. Van Zijl PC, Barker PB. Magnetic resonance spectroscopy and spectroscopic imaging for the study of brain metabolism. Ann N Y Acad Sci 1997
  10. Barker PB, Glickson JD, Bryan RN. In vivo magnetic resonance spectroscopy of human brain tumors. Top Magn Reson Imaging 1993
  11. Tien RD, Lai PH, Smith JS, Lazeyras F. Single-voxel proton brain spectroscopy exam (PROBE/SV) in patients with primary brain tumors. AJR Am J Roentgenol. 1996
  12. Kugel H, Heindel W, Ernestus RI, Bunke J, du Mesnil R, Friedmann G. Human brain tumors: spectral patterns detected with localized H-l MR spectroscopy. Radiology 1992
  13. Go KG, Kamman RL, Mooyaart EL, et al. Localised proton spectroscopy and spectroscopic imaging in cerebral gliomas, with comparison to positron emission tomography. Neuroradiology. 1995
  14. Alger JR, Frank JA, Bizzi A, et al. Metabolism of human gliomas: assessment with H-l MR spectroscopy and F-18 fluorodeoxyglucose PET. Radiology 1990
  15. Lanfermann H, Kugel H, Heindel W, Herholz K, Heiss WD, Lackner K. Metabolic changes in acute and subacute cerebral infarctions: findin